GlobeImmune
Biopharmaceutical company (founded 1995) developing yeast-based, T cell–stimulating therapeutic vaccines for cancer and infectious diseases. Operates laboratory, office and GMP manufacturing space in Louisville, Colorado. Conducts preclinical and clinical development (Phase 1–2) and collaborates with governmental and industry partners on discovery, development and commercialization.
Industries
Nr. of Employees
small (1-50)
Patents
Products
GI-4000 (mutated Ras-targeted vaccine series)
Series of heat-inactivated yeast-based vaccine variants expressing combinations of common Ras mutations; intended to generate Ras-specific T cell responses and administered based on tumor mutation profiling.
GI-6301 (brachyury-targeted vaccine)
Yeast-based vaccine candidate targeting the brachyury protein expressed in several cancers and chordoma, developed to elicit brachyury-specific T cell responses; program was subject to exclusive licensing.
GI-6207 (CEA-targeted vaccine program)
Vaccine program designed to target carcinoembryonic antigen (CEA) for oncology indications.
GS-4774 (HBV therapeutic vaccine)
Therapeutic yeast-based vaccine engineered to present hepatitis B virus antigens from multiple genotypes to stimulate HBV-specific T cell responses, evaluated in Phase 1 and Phase 2 trials in combination with antiviral therapy.
GI-4000 (mutated Ras-targeted vaccine series)
Series of heat-inactivated yeast-based vaccine variants expressing combinations of common Ras mutations; intended to generate Ras-specific T cell responses and administered based on tumor mutation profiling.
GI-6301 (brachyury-targeted vaccine)
Yeast-based vaccine candidate targeting the brachyury protein expressed in several cancers and chordoma, developed to elicit brachyury-specific T cell responses; program was subject to exclusive licensing.
GI-6207 (CEA-targeted vaccine program)
Vaccine program designed to target carcinoembryonic antigen (CEA) for oncology indications.
GS-4774 (HBV therapeutic vaccine)
Therapeutic yeast-based vaccine engineered to present hepatitis B virus antigens from multiple genotypes to stimulate HBV-specific T cell responses, evaluated in Phase 1 and Phase 2 trials in combination with antiviral therapy.
Expertise Areas
- Therapeutic vaccine development
- Oncology immunotherapy
- Infectious disease vaccine development
- Clinical trial management (Phase 1–2)
Key Technologies
- Yeast-based antigen expression
- T cell–focused immunotherapy
- Heat-inactivation of biologic vectors
- Proteomic signature analysis
News & Updates
Press release providing updates on clinical trial progress and developments.
Press release announcing a majority stock sale transaction.
Press release with company updates.
Announcement regarding completion of an initial public offering.
Announcement of presentation of Phase 2 data for a mutation-targeted vaccine in non-small cell lung cancer.
Entered a worldwide strategic collaboration and option agreement for discovery, development and commercialization of certain oncology product candidates, with milestone and royalty provisions; included exercise of options for specific programs.
Press release providing updates on clinical trial progress and developments.
Press release announcing a majority stock sale transaction.
Press release with company updates.
Announcement regarding completion of an initial public offering.
Announcement of presentation of Phase 2 data for a mutation-targeted vaccine in non-small cell lung cancer.
Entered a worldwide strategic collaboration and option agreement for discovery, development and commercialization of certain oncology product candidates, with milestone and royalty provisions; included exercise of options for specific programs.